DrFirst, Imprivata and Forward Advantage Partner to Enable Electronic Prescribing of Controlled Substances for MEDITECH Users

Dallas, TX, May 28, 2014 -- DrFirst, Imprivata® and Forward Advantage today announced a partnership to enable electronic prescribing of controlled substances (EPCS) for users of MEDITECH Client/Server and MAGIC/OSAL EMR platforms. The joint solution integrates leading technologies from DrFirst and Imprivata to allow providers to efficiently and securely prescribe controlled substances electronically.

“EPCS is a critical capability for many medical specialties, and government bodies are beginning to mandate its implementation to help stem drug diversion and doctor shopping,” said Larry O’Toole, associate vice president of strategy and marketing for MEDITECH. “We have seen increased demand from our users for EPCS, and the joint solution from DrFirst and Imprivata combined with Forward Advantage’s MEDITECH expertise provides our customers with a holistic, fully-integrated EPCS solution.”

DrFirst’s EPCS Gold℠ software will be integrated within MEDITECH platforms to enable providers to efficiently and securely prescribe controlled substances electronically. The controlled substance e-prescribing capability will work seamlessly with MEDITECH’s legend-drug e-prescribing workflow, which is also provided by DrFirst.

Imprivata delivers EPCS-specific identity management and authentication capabilities, including fingerprint biometric identification and other two-factor authentication solutions, which are expected to seamlessly integrate with EPCS Gold.

Forward Advantage, a strategic technology solutions partner for MEDITECH and Imprivata customers, will leverage its deep expertise of MEDITECH workflows to help integrate the joint EPCS solution and optimize the benefits for healthcare providers.

Physicians using these MEDITECH solutions will be able to electronically prescribe controlled substances using the same authentication method they use to log into MEDITECH. This streamlines workflows, improves patient satisfaction and increases security by minimizing medication errors.

DrFirst (booth #825), Imprivata (booth #723), and Forward Advantage (booths #531 and #537) will be available to discuss the partnership during the 2014 International MUSE Conference (May 27-30, 2014, in Dallas).

###

About DrFirst
DrFirst pioneers technology solutions that inform the doctor-patient point of encounter, optimizing provider access to patient information, enhancing the doctor's clinical view of the patient, and improving care delivery and clinical outcomes. Its growth is driven by a commitment to innovation, security, and reliability across a wide array of services, including Medication Management, Medication Adherence, and Secure Communication and Collaboration. It has an impressive track record of service to more than 300 EMR/EHR/HIS vendors and an extensive network of providers, hospitals and patients. For more information please visit http://www.drfirst.com.

About Imprivata
Imprivata is a leading provider of authentication and access management solutions for the healthcare industry. Imprivata’s single sign-on, authentication management and secure communications solutions enable fast, secure and more efficient access to healthcare information technology systems to address multiple security challenges and improve provider productivity for better focus on patient care. For more information, please visit http://www.imprivata.com.

About Forward Advantage
Since 1993, Forward Advantage has provided software and services to improve the exchange of information and access to it. Offering products developed in collaboration with MEDITECH for report distribution, HIE products and services, data migration, and identity management, Forward Advantage has over 1,200 installations worldwide and is in the leading position to provide innovative and cost-effective solutions for MEDITECH customers. More information on Forward Advantage’s product and services can be found at http://www.forwardadvantage.com.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.